STOCK TITAN

[SCHEDULE 13G] Albemarle Corporation SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Capital Research Global Investors filed a Schedule 13G reporting beneficial ownership of 6,307,813 shares of Albemarle Corporation common stock, representing 5.3% of the 119,818,504 shares believed outstanding as of the reporting event date. The filing notes that reported holdings include 4,721,204 Convertible Preferred Stocks, which the filer states represent 2,157,590 common shares.

The submission identifies CRGI as an investment management division and includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing is signed by Jae Won Chung on 08/05/2025 and lists issuer and filer addresses.

Capital Research Global Investors ha presentato un Schedule 13G dichiarando la titolarità beneficiaria di 6,307,813 azioni ordinarie di Albemarle Corporation, pari al 5,3% delle 119,818,504 azioni ritenute in circolazione alla data dell'evento comunicato. Il deposito precisa che le partecipazioni riportate includono 4,721,204 azioni privilegiate convertibili, che il dichiarante indica equivalere a 2,157,590 azioni ordinarie.

La comunicazione identifica CRGI come una divisione di gestione degli investimenti e contiene la certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attività commerciale e non allo scopo di modificare o influenzare il controllo dell'emittente. Il documento è firmato da Jae Won Chung il 08/05/2025 e riporta gli indirizzi dell'emittente e del dichiarante.

Capital Research Global Investors presentó un Schedule 13G en el que declara la propiedad beneficiaria de 6,307,813 acciones ordinarias de Albemarle Corporation, lo que representa el 5,3% de las 119,818,504 acciones que se estiman en circulación a la fecha del evento comunicado. La presentación señala que las participaciones informadas incluyen 4,721,204 acciones preferentes convertibles, que el declarante indica que equivalen a 2,157,590 acciones ordinarias.

La comunicación identifica a CRGI como una división de gestión de inversiones e incluye una certificación de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor. El documento está firmado por Jae Won Chung el 08/05/2025 y contiene las direcciones del emisor y del declarante.

Capital Research Global InvestorsSchedule 13G를 제출하여 Albemarle Corporation 보통주 6,307,813주에 대한 실질적 소유권을 신고했으며, 이는 신고일 기준 발행주식수로 추정되는 119,818,504주의 약 5.3%에 해당합니다. 제출서류는 보고된 보유에 4,721,204주의 전환 우선주가 포함되어 있으며, 제출자는 이것이 2,157,590주의 보통주에 해당한다고 명시하고 있습니다.

해당 제출서류는 CRGI를 투자관리 부문으로 식별하며, 이 증권들이 통상적인 영업과정에서 취득·보유된 것이며 발행인의 지배권을 변경하거나 영향을 미칠 목적이 아님을 인증하는 내용을 포함합니다. 문서는 08/05/2025에 Jae Won Chung이 서명했으며 발행인 및 제출자의 주소를 기재하고 있습니다.

Capital Research Global Investors a déposé un Schedule 13G déclarant la propriété bénéficiaire de 6,307,813 actions ordinaires d'Albemarle Corporation, représentant 5,3% des 119,818,504 actions estimées en circulation à la date de l'événement déclaré. le dépôt précise que les participations déclarées incluent 4,721,204 actions privilégiées convertibles, que le déposant indique représenter 2,157,590 actions ordinaires.

La soumission identifie CRGI comme une division de gestion d'investissements et comprend une certification attestant que les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur. Le document est signé par Jae Won Chung le 08/05/2025 et indique les adresses de l'émetteur et du déposant.

Capital Research Global Investors reichte ein Schedule 13G ein und meldete damit die wirtschaftliche Eigentümerschaft von 6,307,813 Aktien der Albemarle Corporation, was 5,3% der geschätzten 119,818,504 ausstehenden Aktien zum Zeitpunkt des gemeldeten Ereignisses entspricht. Die Einreichung weist darauf hin, dass die gemeldeten Bestände 4,721,204 wandelbare Vorzugsaktien enthalten, die der Einreicher als 2,157,590 Stammaktien angibt.

Die Mitteilung identifiziert CRGI als eine Investment-Management-Abteilung und enthält eine Bescheinigung, dass die Wertpapiere im gewöhnlichen Geschäftsverlauf erworben und gehalten werden und nicht zum Zwecke einer Änderung oder Beeinflussung der Kontrolle des Emittenten. Das Dokument ist von Jae Won Chung am 08/05/2025 unterzeichnet und nennt die Adressen des Emittenten und des Einreichers.

Positive
  • Disclosure of material stake: Reports beneficial ownership of 6,307,813 shares (5.3%), a material disclosure for investors.
  • Transparency on convertible instruments: States that 4,721,204 Convertible Preferred Stocks represent 2,157,590 common shares included in the total.
  • Certification of passive intent: Filers certify holdings are held in the ordinary course and not for control purposes.
Negative
  • None.

Insights

TL;DR: Capital Research reports a passive 5.3% stake (6.31M shares) in Albemarle on Schedule 13G.

Capital Research Global Investors discloses ownership of 6,307,813 shares, equal to 5.3% of Albemarle's ~119.8M shares outstanding. The filing explicitly counts 4,721,204 Convertible Preferred Stocks as representing 2,157,590 common shares in its total. This is a standard passive disclosure under a Schedule 13G format and includes the filer's certification that the stake is held in the ordinary course of business and not to influence control. For market impact, the position is material in size but presented as non-control.

TL;DR: Filing confirms passive ownership and an explicit certification that holdings are not intended to change control.

The Schedule 13G includes a formal certification stating the securities "were acquired and are held in the ordinary course of business" and "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of Albemarle. The document is signed by a Capital Research officer on 08/05/2025. The disclosure aids transparency for board and governance monitoring but contains no indication of active governance intent.

Capital Research Global Investors ha presentato un Schedule 13G dichiarando la titolarità beneficiaria di 6,307,813 azioni ordinarie di Albemarle Corporation, pari al 5,3% delle 119,818,504 azioni ritenute in circolazione alla data dell'evento comunicato. Il deposito precisa che le partecipazioni riportate includono 4,721,204 azioni privilegiate convertibili, che il dichiarante indica equivalere a 2,157,590 azioni ordinarie.

La comunicazione identifica CRGI come una divisione di gestione degli investimenti e contiene la certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attività commerciale e non allo scopo di modificare o influenzare il controllo dell'emittente. Il documento è firmato da Jae Won Chung il 08/05/2025 e riporta gli indirizzi dell'emittente e del dichiarante.

Capital Research Global Investors presentó un Schedule 13G en el que declara la propiedad beneficiaria de 6,307,813 acciones ordinarias de Albemarle Corporation, lo que representa el 5,3% de las 119,818,504 acciones que se estiman en circulación a la fecha del evento comunicado. La presentación señala que las participaciones informadas incluyen 4,721,204 acciones preferentes convertibles, que el declarante indica que equivalen a 2,157,590 acciones ordinarias.

La comunicación identifica a CRGI como una división de gestión de inversiones e incluye una certificación de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor. El documento está firmado por Jae Won Chung el 08/05/2025 y contiene las direcciones del emisor y del declarante.

Capital Research Global InvestorsSchedule 13G를 제출하여 Albemarle Corporation 보통주 6,307,813주에 대한 실질적 소유권을 신고했으며, 이는 신고일 기준 발행주식수로 추정되는 119,818,504주의 약 5.3%에 해당합니다. 제출서류는 보고된 보유에 4,721,204주의 전환 우선주가 포함되어 있으며, 제출자는 이것이 2,157,590주의 보통주에 해당한다고 명시하고 있습니다.

해당 제출서류는 CRGI를 투자관리 부문으로 식별하며, 이 증권들이 통상적인 영업과정에서 취득·보유된 것이며 발행인의 지배권을 변경하거나 영향을 미칠 목적이 아님을 인증하는 내용을 포함합니다. 문서는 08/05/2025에 Jae Won Chung이 서명했으며 발행인 및 제출자의 주소를 기재하고 있습니다.

Capital Research Global Investors a déposé un Schedule 13G déclarant la propriété bénéficiaire de 6,307,813 actions ordinaires d'Albemarle Corporation, représentant 5,3% des 119,818,504 actions estimées en circulation à la date de l'événement déclaré. le dépôt précise que les participations déclarées incluent 4,721,204 actions privilégiées convertibles, que le déposant indique représenter 2,157,590 actions ordinaires.

La soumission identifie CRGI comme une division de gestion d'investissements et comprend une certification attestant que les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur. Le document est signé par Jae Won Chung le 08/05/2025 et indique les adresses de l'émetteur et du déposant.

Capital Research Global Investors reichte ein Schedule 13G ein und meldete damit die wirtschaftliche Eigentümerschaft von 6,307,813 Aktien der Albemarle Corporation, was 5,3% der geschätzten 119,818,504 ausstehenden Aktien zum Zeitpunkt des gemeldeten Ereignisses entspricht. Die Einreichung weist darauf hin, dass die gemeldeten Bestände 4,721,204 wandelbare Vorzugsaktien enthalten, die der Einreicher als 2,157,590 Stammaktien angibt.

Die Mitteilung identifiziert CRGI als eine Investment-Management-Abteilung und enthält eine Bescheinigung, dass die Wertpapiere im gewöhnlichen Geschäftsverlauf erworben und gehalten werden und nicht zum Zwecke einer Änderung oder Beeinflussung der Kontrolle des Emittenten. Das Dokument ist von Jae Won Chung am 08/05/2025 unterzeichnet und nennt die Adressen des Emittenten und des Einreichers.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Capital Research Global Investors
Signature:Jae Won Chung
Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
Date:08/05/2025

FAQ

Who filed the Schedule 13G for Albemarle (ALB)?

The filing was made by Capital Research Global Investors, a division of Capital Research and Management Company.

How many Albemarle (ALB) shares does Capital Research report owning?

The filer reports beneficial ownership of 6,307,813 shares, representing 5.3% of shares outstanding.

Does the filing indicate the stake is for control of Albemarle (ALB)?

No. The Schedule includes a certification that the securities are held in the ordinary course of business and not to change or influence control.

Are convertible securities included in the reported share total?

Yes. The filing states 4,721,204 Convertible Preferred Stocks are included and represent 2,157,590 common shares.

When was the Schedule 13G signed?

The signature block shows the filing was signed by Jae Won Chung on 08/05/2025.
Albemarle Corp

NYSE:ALB

ALB Rankings

ALB Latest News

ALB Latest SEC Filings

ALB Stock Data

9.50B
117.17M
0.39%
98.76%
12.52%
Specialty Chemicals
Plastic Materials, Synth Resins & Nonvulcan Elastomers
Link
United States
CHARLOTTE